Medical Device and Diagnostics
News & Jobs
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


 Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 

 Company News
Bristol-Myers Squibb (BMY) Prices €1.15 Billion Of Senior Notes 4/30/2015 10:01:37 AM
Bristol-Myers Squibb (BMY) Announces Cash Tender Offer For Up To $400 Million Aggregate Principal Amount Of Its Outstanding Debt Securities 4/28/2015 12:46:27 PM
Bristol-Myers Squibb (BMY) Reports First Quarter Financial Results 4/28/2015 12:00:09 PM
Bristol-Myers Squibb (BMY) Popular Amongst Latest 13F Filers 4/28/2015 7:17:33 AM
Bristol-Myers Squibb (BMY) Release: ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% Of Post-Liver Transplant Patients With Hepatitis C And Up To 94% Of Hepatitis C Patients With Cirrhosis (Child-Pugh Class A Or B) 4/27/2015 8:48:30 AM
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion In The European Union For Opdivo (Nivolumab) For The Treatment Of Advanced Melanoma In Both First-Line And Previously Treated Patients 4/24/2015 8:32:42 AM
Bristol-Myers Squibb (BMY) Release: First Randomized Study Evaluating Opdivo (Nivolumab)+Yervoy (Ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone In Patients With Previously Untreated Advanced Melanoma 4/20/2015 1:18:26 PM
Is Bristol-Myers Squibb (BMY) About To Fall Apart? 4/20/2015 6:46:26 AM
Bristol-Myers Squibb (BMY) Soars After Halting Study Early As Opdivo Aces Test Again 4/17/2015 7:07:53 AM
Eli Lilly (LLY) Snags North American Rights to Erbitux From Bristol-Myers Squibb (BMY) 4/16/2015 11:21:53 AM